Acta Scientific Ophthalmology (ISSN: 2582-3191)

Research Article Volume 4 Issue 9

Endophthalmitis Following Intravitreal Injection Bevacizumab in an Operation Room Setting of Nepal

Hara Maya Gurung, Eliya Shrestha, Babita Gurung, Hari Bikram Adhikari and Pawan Baral*

Himalaya Eye Hospital, Pokhara, Nepal

*Corresponding Author: Pawan Baral, Himalaya Eye Hospital, Pokhara, Nepal.

Received: July 30, 2021; Published: August 13, 2021

Abstract

Purpose: Intravitreal injection Bevacizumab (IVB) has become an important tool in the armamentarium of retina specialists. Though it is considered safe, it is not completely free from causing endophthalmitis, a devastating ocular inflammation which leads to loss of vision. The purpose of this study is to find the prevalence of endophthalmitis following IVB in the operation room of Himalaya Eye Hospital (HEH).

Methods: A retrospective study of the patients who received IVB in the operation room of HEH from January 2015 to March 2021 was done. During this period, the record of the number of IVB performed and the number of patients who got endophthalmitis post IVB was taken from the database of the operation room and subsequently the details of the endophthalmitis cases were studied. Nepal Health Research Council approved this study (no 3085).

Results: A total of 3339 IVB were performed for 2105 eyes from January 2015 to March 2021. An outbreak of a single episode of cluster endophthalmitis, sterile in nature, was observed during this period which accounted to the prevalence of 0.209% of endophthalmitis following IVB in our hospital.

Conclusion: The prevalence of endophthalmitis following IVB in HEH is low. IVB which is gaining popularity in the treatment of retinal diseases, if performed with caution is safe and beneficial to the patients.

Keywords: Bevacizumab; Endophthalmitis; Prevalence; Retinal Diseases; Retina Specialists

References

  1. Chen Y., et al. “Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China”. Journal of Ophthalmology1 (2020): 60-63.
  2. Cheema RA., et al. “Incidence of endophthalmitis following intravitreal Bevacizumab injection at a tertiary care hospital in Eastern Province of Saudi Arabia”. Saudi Journal of Ophthalmology2 (2015): 135-136.
  3. Yamashiro K., et al. “Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch”. Retina3 (2010): 485-490.
  4. Khan P., et al. “Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial”. Indian Journal of Ophthalmology9 (2016): 694-696.
  5. Artunay O., et al. “Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection”. Eye12 (2009): 2187-2193.
  6. Lau PE., et al. “Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections”. Journal of Ophthalmology (2018).
  7. Ta CN. “Minimizing the risk of endophthalmitis following intravireos injections”. Retina (2004).
  8. Cheung CSY., et al. “Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections”. Ophthalmology 8 (2012): 1609-1614.
  9. Kim SJ., et al. “Antibiotic resistance of conjunctiva and nasopharynx evaluation study: A prospective study of patients undergoing intravitreal injections”. Ophthalmology12 (2010): 2372-2378.
  10. Labardini CP and Blumenthal EZ. “Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents”. Rambam Maimonides Medical Journal 4 (2018): e0032.
  11. Pradhan E., et al. “Acute Endophthalmitis after Intravitreal Bevacizumab Injections at The Tertiary Centre in Nepal”. Nepalese Journal of Ophthalmology 1 (2018): 107-110.
  12. Entezari M., et al. “Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab”. Indian Journal of Ophthalmology 4 (2014): 468-471.

Citation

Citation: Pawan Baral., et al. “Endophthalmitis Following Intravitreal Injection Bevacizumab in an Operation Room Setting of Nepal".Acta Scientific Ophthalmology 4.9 (2021): 17-21.

Copyright

Copyright: © 2021 Pawan Baral., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 25, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US